{"name":"Verrica Pharmaceuticals Inc.","slug":"verrica-pharmaceuticals-inc","ticker":"","exchange":"","domain":"verrica.com","description":"Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for skin diseases. The company's pipeline includes several drug candidates in various stages of clinical development, with a strong emphasis on dermatological conditions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":35577000,"revenueGrowth":370.2,"grossMargin":0,"rdSpend":8855000,"netIncome":-17886000,"cash":47131000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOSWlhSFNoWkRhMWptMGx5V2prN09oZ2dqRGhRSmRRcG5CSE5uSkR3WkE3ZnB0ZFpDTS1LWVd2UG9PZU1wVHBOdnBJbmRwWVdvUElpbFZ6Z3Zic2pnd2liTVQ5RDVZanQ3MmpXb1RObTJCMHp0RDYxUDlkdG0yUlRLT3V4eFVqWWllMHFNZDlMdGZvRFJSeC05TVRCUlRaekpsYzJ6S3JJVERnZUR4SWdNQ3FvdENtVnBLbzVxSllB?oc=5","date":"2026-02-12","type":"pipeline","source":"Stock Titan","summary":"VTAMA launch leader joins Verrica to drive YCANTH skin treatment - Stock Titan","headline":"VTAMA launch leader joins Verrica to drive YCANTH skin treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOYThaQjFCMTRTdzBDc2ZxYTcyNGtjdEw2MnRFMHNnMVNDUEV6LVRCdFA2b1Nqd196YWJIeGc1SW5TUVBxWFBaYlRCWFREQjQxSVktXzZNTVFtSVVEQnFKTU9vcDIwd2kyVW50LUtxNjhoWlIyZlFxUWJLT3pkbWhub3BFVkx3aVJNanJDQjNXbFgzY1labmc3UUNUX3N2T2hwbE5NaVdvenFLSmxqRFFjb3h3T1BJeWpzeW4tZmFZQmNYUk4zRm54SXVqUFJkd0dBZXdET1ZWWWVhbnFzZHM0MTlvaExid0tCVDFORXhKUUZkczFDVkFqQ0hacFR3Sm0ybXpGVnJpamlSUDZUcHB3S2dXMW5MdUdvdVltRWpQb09sZXJOYUZxci1FRW5LQXc?oc=5","date":"2026-02-09","type":"pipeline","source":"GlobeNewswire","summary":"Verrica Pharmaceuticals Announces Launch of YCANTH® for the - GlobeNewswire","headline":"Verrica Pharmaceuticals Announces Launch of YCANTH® for the","sentiment":"neutral"},{"date":"2025-12-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOajZKR3VlQnBhWWdVOUd4dTlSUENlaU5UdDdSSlp4dElLdTBNbFctbFRFUW1hNlloZXlveGdMZi0tblJqam5jellxbHlRSEdmbk1RamI4ZUN5VjlKVHFBQlNYRUNHYTlOdnVaNlZGeDJMNVBwRjl5ZmlPZy1Yam56cmUzbWRxaDJVLXk3UWZabUhKQUlWZU9JSWRzR2RXSW5rVUN5Rm1VeDZfZTdIcXc?oc=5","date":"2025-11-24","type":"pipeline","source":"The Business Journals","summary":"Verrica arranges $50M financing to pay off debt, pursue 'billion-dollar market opportunities' - The Business Journals","headline":"Verrica arranges $50M financing to pay off debt, pursue 'billion-dollar market opportunities'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQk1OcFIzZjlFM3NoVHBSdG1oTFA0R1NFR3UzRTBKODFTZGVNTHZtRVBwTTNfdWU5THMydi1LSEl0NXN6eEZsckhVZVdJeWNVaW5JTkwxQlhHYTB6czBUWHZHaHJDck42U05RcU5MdFJEUUE5YU9ubVpBN2ZqT1R6dUF3LU04bzkz?oc=5","date":"2025-11-17","type":"earnings","source":"Yahoo Finance","summary":"Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance","headline":"Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ...","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ0hhNHk4WXhTQUEyY2Vzam4wY3dSZDl0V2NQQTl2WGF6ZXNCemc1em5XWjhTSlFldnFLNVBNM01pN1kxYldVWUs1UXVld1hQUDVqNEJKQXhBU1VaVVR2d3hYY2hxb1gyNGZJdlc0UXZPMjg0S1BESkFNdy02Q2ZlekhTWU9oZ3FlRUpiTGE0Qmh2aG9pTlBlUE53VU4xU0px?oc=5","date":"2025-09-19","type":"regulatory","source":"Yahoo Finance","summary":"Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum - Yahoo Finance","headline":"Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPYm9lX1pNX0l1dGpnZ1l6WU4xWWM2UGdRTXBIeEZXa0ZYUS1xSDRkaGViVzNhQ0ZCaVdtUEg0Wjc1TzZDZHZISmZuYi0zaHh4Q3N2ZHJMeVVmQ1hVN3NwaFpjcEN6LUFuaVd5d1BhN3VVNUx0bnZxa1l2b1VZQkM0RXJWY3Y0akpKVllhVXhsTmU4RUdXdEFRaGRIaTBSLVQ3MVplOElld1pySVBaTDVGZF93Vy1Zd1hvQjVZ?oc=5","date":"2025-07-01","type":"trial","source":"Stock Titan","summary":"Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market - Stock Titan","headline":"Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQSXJuTTQ3Q2FaX0MtTW5HNGluQU1HdFJwWUJNRFhuWWIzMG16NGZMRjBSa05xMlZMQ0c4SExzRHVqdHBXUWtnLTRwckFvT25vdVluSEdxa1o1V3FLMVB2OWdxTld5UEJVVVJDZXdrYTJRVjhQcWZhWVBQd3dKeHA3NnY5SDZXVDlzUWcxYm93?oc=5","date":"2025-06-12","type":"pipeline","source":"Yahoo Finance","summary":"Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance","headline":"Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOSnBlVkZkWWpfVmU4T3dtcXJINGMxQlUteXdVVlNIUEJOcFJnZmxiaXV6emdZUjBaTURUWVJjajlNTXFpT3JhSTRFdjJPOWxja1d6dU4tTmx4c1k4VDFtMmdlYVVqOXJhcS16R1RHaC1pUHBuaF85NHlPMHFiRUVLbWJGVXNQanZYZW83emZnVnJra25Q?oc=5","date":"2025-03-12","type":"earnings","source":"RTTNews","summary":"Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - RTTNews","headline":"Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPQmRSUUpCMnVpRWpiY09sSEhFQTdqd0VlZ1JzamNpaFp0SUhyUWgzbVlfRlhUTXdQdFNQV3pCcWtGeTY4cXBRUkpPaDVTWFJGRFFaeklqelVLQ0JvOTNja1M3UWNTZ0VKTkZFaVQ3TU9XbzdHd09BeUdoVHE4WnAtXzNaWm50M05wSHh4SnhTNnFHNXg3dGkxY3oySnM1WU44YWR1NjdmYXk5SzFLNEhncXBOaWh2YzFlcU0tcUwtSXBiRm1HeUJpLWxXYlBBdnFGYTJLdzlBdw?oc=5","date":"2025-03-11","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com","headline":"Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2024-10-11","type":"pipeline","source":"Business Wire","summary":"VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA ","headline":"VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBlQ0U3UGxTVTNpY3prdlVOYU5jWXN0S19RYVBkTHlucUt2ZmZSV0o1ZEdodVJ3V3VUdi16cFBDX2RKUHlya1hoUVVrNzZUU3FL?oc=5","date":"2023-12-15","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":35577000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":35577000,"period":"2025-12-31"},{"value":7566000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8855000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17886000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":47131000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}